Related Experiment Video
Updated: Jun 29, 2026

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction
Published on: April 1, 2019
Technological Interventions for Dry Eye Disease: A Systematic Review and Random-Effects Network Meta-analysis of
Dror Ben Ephraim Noyman1,2, Clara C Chan3,2, Joshua C Teichman3,2
1Ophthalmology Department, Rambam Health Care Campus, Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
TearCare with meibomian gland expression and intense pulsed light therapies show superior efficacy for dry eye disease (DED) at 2-4 months. These advanced treatments improved objective and subjective DED outcomes compared to other methods.
Area of Science:
- Ophthalmology
- Biomedical Engineering
- Medical Technology
Background:
- Dry eye disease (DED) pathophysiology is increasingly targeted by novel therapeutic technologies.
- Emerging modalities aim to address the complex mechanisms underlying DED.
Purpose of the Study:
- To systematically evaluate and compare the efficacy of various technological interventions for DED.
- To rank the effectiveness of different treatments based on objective and subjective outcomes.
Main Methods:
- A systematic review and network meta-analysis of randomized controlled trials (RCTs) from PubMed, Scopus, and Embase.
- Included interventions: intense pulsed light (IPL), thermal pulsation, TearCare, iLux, low-level light therapy (LLLT), transcutaneous electrical stimulation (TES), and quantum molecular resonance (QMR) therapy.
- Evaluated outcomes: tear break-up time (TBUT), Schirmer test, corneal staining, meibomian gland quality, and symptom severity at 2-4 months post-treatment.
Main Results:
- Forty-seven RCTs involving 3581 patients were analyzed.
- TearCare with meibomian gland expression (MGX) and IPL with a heated eye mask (HEM) showed highest TBUT improvement.
- QMR therapy was most effective for corneal staining; TearCare with MGX led in meibomian gland secretion quality.
- IPL-based modalities, particularly IPL plus HEM, demonstrated superior symptom relief.
Conclusions:
- TearCare with MGX and IPL-based protocols offer superior efficacy for DED outcomes at 2-4 months.
- These technologies outperform other interventions and conservative treatments.
- Further standardized, long-term comparative studies are necessary to confirm findings.
More Related Videos
06:29Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
Published on: May 2, 2020
07:36Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems